en · de · es · pt
peptide-index.peptides5388.com › News › Background And Pharmacological Mechanism — Questions and Answers

Background And Pharmacological Mechanism — Questions and Answers

By Editorial Desk · published 2026-01-23 · last reviewed 2026-03-08 · News

This is a working overview of anti-doping, written for readers who want more than a one-paragraph summary but less than a textbook.

This page was last updated on 2026-03-08 and is reviewed periodically as new material appears.

Background and Pharmacological Mechanism

SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.

SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.

SR9009 Background and Receptor Mechanism

Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.

SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.

SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.

Sr9009 at a glance

PropertyValueNotes
Molecular formulaC20H24ClN3O4SReported for the free base
Molecular weight437.9 g/molCalculated from the formula
Primary targetREV-ERBα and REV-ERBβNuclear receptors involved in circadian regulation
SolubilitySoluble in DMSO and ethanolPoorly soluble in water
Typical storage-20 °C, desiccatedProtect from light and moisture

Regulation, Testing, and Storage

Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.

Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.

SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.

Related pages on this site

Supporting material

== History == The earliest recorded use of the internal standard method dates back to Gouy's flame spectroscopy work in 1877, where he used an internal standard to determine if the excitation in his flame was consistent. His experimental procedure was later reintroduced in the 1940s, when recording flame photometers became readily available. The use of internal standards continued to grow, being applied to a wide range of analytical techniques including nuclear magnetic resonance (NMR) spectroscopy, chromatography, and inductively coupled plasma spectroscopy.

== Disorders == Women who have been on relaxin treatment during unrelated clinical trials have experienced heavier bleeding during their menstrual cycle, suggesting that relaxin levels could play a role in abnormal uterine bleeding. However, more research is needed to confirm relaxin as a direct cause. A lower expression of relaxin has been found amongst women who have endometriosis. The research in this area is limited and more studying of relaxin's contribution could contribute greatly to the understanding of endometriosis. Specific disorders related to relaxin have not been heavily described, yet a link to scleroderma and fibromyalgia has also been suggested.

Yohimbine is a substance found in the bark of yohim trees in West Africa. It was traditionally used in West African cultures, in which the bark would be boiled and the resulting water drunk until it increased sexual desire. It is also found in over-the-counter health products. Yohimbine is an indole alkaloid and is an adrenoceptor antagonist. Known adverse effects include nausea, anxiety, irregular heartbeats, and restlessness.

On some narrow-gauge lines in Europe, and on the Paris Metro, a simplified version of the loose-coupler is used, consisting of a single central buffer with a chain underneath. Sometimes there are two chains, one on each side of the coupler. The chain usually contains a screw-adjustable link to allow close coupling. These variants are also used elsewhere. On sharp curves, a single centre buffer is less likely to be subject to buffer-locking. The Eritrean Railway also uses a centre buffer and chain coupler.

=== DNA barcoding and genomics === DNA sequences derived from fungarium specimens can link preserved material to molecular characters used in identification and phylogenetic studies, extending the scientific value of collections beyond traditional morphological characters. Sequencing named fungarium specimens can also expand public reference-sequence databases, improving the interpretation of environmental fungal DNA that would otherwise remain unidentified or only insufficiently identified. DNA in historical specimens is often degraded into short fragments of 40–400 base pairs. Genetic quality is influenced by the specimen's age as well as past exposure to heat, chemicals, or moisture. Consequently, older specimens are less likely to yield uncontaminated internal transcribed spacer (ITS) sequences than more recent collections, often producing DNA from contaminant organisms instead. DNA degradation depends not only on age but also on how specimens were collected, dried, stored, and treated against pests, because historical methods often prioritized preservation of morphology rather than nucleic-acid integrity. Conventional PCR amplification and Sanger sequencing can be difficult or impossible for some specimens, including some type material, owing to fragmentation and contamination by exogenous fungal DNA.

Sources: en.wikipedia.org

Notes from published material

A trial with the primary objective of showing that the response to two or more treatments differs by an amount which is clinically unimportant. This is usually demonstrated by showing that the true treatment difference is likely to lie between a lower and an upper equivalence margin of clinically acceptable differences. (ICH E9) Essential Documents

Cultivation is successful in climates with hot summers, with optimum growing conditions in mean temperatures of 20 to 30 °C (70 to 85 °F); temperatures of below 20 °C (70 °F) and over 40 °C (105 °F) stunt growth significantly. They can grow in a wide range of soils, with optimum growth in moist alluvial soils with good organic content. Soybeans, like most legumes, perform nitrogen fixation by establishing a symbiotic relationship with the bacterium Bradyrhizobium japonicum (syn. Rhizobium japonicum; Jordan 1982). This ability to fix nitrogen allows farmers to reduce nitrogen fertilizer use and increase yields when growing other crops in rotation with soy. There may be some trade-offs, however, in the long-term abundance of organic material in soils where soy and other crops (for example, corn) are grown in rotation. For best results, though, an inoculum of the correct strain of bacteria should be mixed with the soybean (or any legume) seed before planting. Modern crop cultivars generally reach a height of around 1 m (3 ft), and take 80–120 days from sowing to harvesting.

=== General and cited sources === Belladelli, Federico; Del Giudice, Francesco; Glover, Frank; Mulloy, Evan; Muncey, Wade; Basran, Satvir; Fallara, Giuseppe; Pozzi, Edoardo; Montorsi, Francesco; Salonia, Andrea; Eisenberg, Michael L. (2023). "Worldwide Temporal Trends in Penile Length: A Systematic Review and Meta-Analysis". The World Journal of Men's Health. 41 (4): 848–860. doi:10.5534/wjmh.220203. PMC 10523114. PMID 36792094. "Men worry more about penile size than women, says 60-year-old research review" (Press release). Blackwell. 31 May 2007. Archived from the original on 21 April 2021. Retrieved 11 August 2018. Cakir, Omer Onur; Pozzi, Edoardo; Castiglione, Fabio; Alnajjar, Hussain M.; Salonia, Andrea; Muneer, Asif (March 2021). "Penile Length Measurement: Methodological Challenges and Recommendations, a Systematic Review". The Journal of Sexual Medicine. 18 (3): 433–439. doi:10.1016/j.jsxm.2020.11.012. PMID 33648901. Lauersen, Niels; Whitney, Steven (1983). It's Your Body: A Woman's Guide to Gynecology (3rd ed.). New York: Berkley Publishing. p. 480. ISBN 978-0-425-09917-9. Lee, P. A; Mazur, T; Danish, R; Amrhein, J; Blizzard, R. M; Money, J; Migeon, C. J (1980). "Micropenis. I. Criteria, etiologies and classification". The Johns Hopkins Medical Journal. 146 (4): 156–63. PMID 7366061. NAID 10010056499. Loos, Shirley; De Wil, Peter; Delcarte, Leslie; Serefoglu, Ege Can; Van Renterghem, Koenraad; Ward, Sam (September 2023). "The effect of penis size on partner sexual satisfaction: a literature review". International Journal of Impotence Research. 35 (6): 519–522.

=== Producer/Engineer === Jawbreaker - "Chesterfield King" EP (Communion/Tupelo, 1991) Jawbreaker - Bivouac (Communion/Tupelo, 1991) Warlock Pinchers - Circusized Peanuts (Boner Records, 1991) Blister - Glitches (1992) (Executive Producer) Tumor Circus - Tumor Circus (Alternative Tentacles, 1991) Jello Biafra - I Blow Minds for a Living (Alternative Tentacles, 1991)

Sources: en.wikipedia.org

Background from the literature

=== Off-label drugs === α2-Adrenergic receptor agonists (e.g., clonidine, dexmedetomidine, guanfacine) – opioid withdrawal Benzodiazepines (e.g., diazepam) – GABAA receptor positive allosteric modulators – alcohol withdrawal syndrome Gabapentinoids (e.g., gabapentin, pregabalin) – α2δ subunit-containing voltage-gated calcium channel blockers – alcohol withdrawal syndrome Ibogaine (Tabernanthe iboga) – various actions, oneirogen/hallucinogen – opioid use disorder Lobeline – nicotinic acetylcholine receptor agonist – smoking withdrawal Mecamylamine – nicotinic acetylcholine receptor antagonist – smoking withdrawal Nicotine (nicotine replacement therapy; e.g., nicotine gum, nicotine inhaler, nicotine lozenge, nicotine nasal spray, nicotine patch) – nicotinic acetylcholine receptor agonist – smoking withdrawal Phenibut (Anvifen) – GABAB receptor agonist and gabapentinoid (α2δ subunit-containing voltage-gated calcium channel blocker) – alcoholism and alcohol withdrawal syndrome Serotonergic psychedelics (e.g., psilocybin, LSD, mescaline, DMT) – serotonin 5-HT2A receptor agonists and psychedelic hallucinogens – various substance use disorders Topiramate (Topamax) – various actions – alcoholism and alcohol withdrawal syndrome

=== Glucagon Secretion and Control of Gluconeogenesis === Glucagon functions to signal the liver to begin gluconeogenesis which increases glucose levels in the blood. Glucagon will bind to the glucagon receptors on the plasma membranes of hepatocytes (liver cells). This ligand binding causes the activation of adenylate cyclase, which causes the creation of cyclic AMP (cAMP). As the intracellular concentration of cAMP rises, protein kinase A (PKA) is activated and phosphorylates the transcription factor cAMP Response Element Binding (CREB) protein. CREB then induces transcription of glucose-6-phosphatase and phosphoenolpyruvate carboxylase (PEPCK). These enzymes increase gluconeogenic activity. PKA also phosphorylates phospho-fructokinase 2 (PFK2)/fructose 2,6-biphsophatase (FBPase2), inhibiting PFK2 and activating FBPase2. This inhibition decreases intracellular levels of fructose 2,6-biphosphate and increases intracellular levels of fructose 6-phosphate which decreases glycolytic activity and increases gluconeogenic activity. PKA also phosphorylates pyruvate kinase which causes an increase in intracellular levels of fructose 1,6-biphosphate and decreases intracellular levels of pyruvate, further decreasing glycolytic activity. The most important action of PKA in regulating gluconeogenesis is the phosphorylation of phosphorylase kinase which acts to initiate the glycogenolysis reaction, which is the conversion of glycogen to glucose, by converting glycogen to glucose 1-phosphate. Glucagon is a peptide hormone derived from the proglucagon precursor.

Bully: Andy Height: 6'2 Weight: 199 lbs Victim(s): Steven and Taylor Fighter: Jason "Mayhem" Miller Height: 6'1 Weight: 198 lbs Money earned by Bully: $0 Money earned by victim(s): $10,000 Original airing:

In 2010, shortly after the company's 50th anniversary, Domino's changed its pizza recipe "from the crust up", making significant changes in the dough, sauce, and cheese used in their pizzas. Their advertising campaign admitted to earlier problems with the public perception of Domino's product owing to taste issues. In September 2012, Domino's announced it was reformulating their pan pizza recipe, and the new version would debut on the menu on September 24, 2012,. In December 2013, Domino's Pizza Israel unveiled its first vegan pizza, which uses a soy-based cheese substitute supplied by the UK company VBites.

=== Perioperative medicine === Clonidine is sometimes used in perioperative medicine as an adjunctive therapy during the perioperative period, where it is administered alongside other analgesics to provide sedation and pain-control. Whilst clonidine itself has limited clinical utility as a monotherapy for postoperative pain, its combination with opioid medications may allow adequate pain relief to be achieved at lower opioid doses, which may reduce the frequency and severity of opioid-related adverse effects. Compared with other sedative and opioid medications used perioperatively, clonidine does not produce respiratory depression or anterograde amnesia. Moreover, its hemodynamic-stabilising effects and ability to reduce postoperative shivering are considered particularly useful in patients at high risk of myocardial ischaemia. Clonidine also has anxiolytic properties that may help reduce preoperative anxiety. In perioperative settings, clonidine may be orally ingested during the preoperative stage or administered intravenously or intramuscularly immediately before, during or shortly after surgery. Clonidine can also be administered via epidural or intrathecal catheters as an adjuvant to local anesthetics to enhance perioperative and postoperative neuraxial blockade. Clonidine's analgesic effects are attributed in part to activation of α2 adrenoreceptors within the dorsal horn of the spinal cord, which inhibits the release of pronociceptive neurotransmitters from primary afferent terminals and hyperpolarizes nociceptive interneurons.

Sources: en.wikipedia.org

Frequently asked questions

What is SR9009?

It is a synthetic REV-ERB agonist used mainly in preclinical research. It is not an approved medicine for human use.

How does it work?

It binds to REV-ERBα and REV-ERBβ, nuclear receptors involved in circadian and metabolic gene regulation. This can alter transcription of genes related to lipid and glucose metabolism in experimental models.

Is it proven to increase endurance in humans?

No controlled human trials have established that effect. Endurance findings come primarily from rodent studies, and human responses remain unknown.

What is SR9009?

SR9009 is a synthetic research compound that acts on REV-ERB nuclear receptors. It is not approved for human use and is sold only as a research chemical. Its effects have been studied mainly in cells and rodents.

Network